Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years

NCT04560881 is registered in ClinicalTrials.gov with Laboratorio Elea Phoenix S.A. as lead sponsor.

NCT NCT04560881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04560881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years
Lead sponsor
Laboratorio Elea Phoenix S.A.
Phase
Phase 3
Overall status
Completed
Start date
September 16, 2020
Completion date
December 13, 2021
Enrollment
3,000 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 virus infection